Alzheimer’s & Dementia: Translational Research & Clinical Interventions (Jan 2020)

Effect of apolipoprotein E ε4 allele on the progression of cognitive decline in the early stage of Alzheimer's disease

  • Kazushi Suzuki,
  • Akihiro Hirakawa,
  • Ryoko Ihara,
  • Atsushi Iwata,
  • Kenji Ishii,
  • Takeshi Ikeuchi,
  • Chung‐Kai Sun,
  • Michael Donohue,
  • Takeshi Iwatsubo,
  • Alzheimer's Disease Neuroimaging Initiative, Japanese Alzheimer's Disease Neuroimaging Initiative

DOI
https://doi.org/10.1002/trc2.12007
Journal volume & issue
Vol. 6, no. 1
pp. n/a – n/a

Abstract

Read online

Abstract Introduction Possession of the apolipoprotein E (APOE) ε4 allele advances amyloid β (Aβ) deposition and symptomatic onset of Alzheimer's disease (AD), whereas its effect on the rate of cognitive decline remained controversial. We examined the effects of APOE ε4 allele on cognition in biomarker‐confirmed late mild cognitive impairment (LMCI) and mild AD subjects in the Japanese Alzheimer's Disease Neuroimaging Initiative (J‐ADNI) and North American ADNI (NA‐ADNI). Methods The “early AD” (ie, combined LMCI and mild AD) cohort of 649 subjects from J‐ADNI and NA‐ADNI were selected based on positivity of Aβ confirmed by amyloid positron emission tomography (PET) or cerebrospinal fluid testing. The rates of cognitive decline in the Mini Mental State Examination (MMSE), the Clinical Dementia Rating Sum of Boxes (CDR‐SB), and the Alzheimer's Disease Assessment Scale‐cognitive subscale 13 (ADAS‐Cog) from baseline were examined using mixed‐effects model. The effect of ε4 on time to conversion to dementia was also analyzed in LMCI using the Kaplan‐Meier estimator and log‐rank test. Results The rates of cognitive decline were not significantly different between ε4 carriers and ε4 non‐carriers in the total early AD cohort, which were affected neither by region nor by the number of ε4 alleles. In LMCI, ε4 carriers showed almost the same progression rates as ε4 non‐carriers, except for a significantly faster decline in MMSE (P = .0282). Time to conversion to demenita was not significantly different between ε4 carriers and ε4 non‐carriers. In ε4‐positive mild AD, the rates of decline in MMSE (P = .003) and CDR‐SB (P = .0071) were slower than those in ε4 non‐carriers. DISCUSSION The APOE ε4 allele had little effect on the rates of cognitive decline in the overall biomarker‐confirmed early AD, regardless of region and number of ε4 alleles, with a slight variability in different clinical stages, the ε4 allele being slightly accelerative in LMCI, while decelerative in mild AD.

Keywords